Oxford Immunotec has announced that its T-SPOT.COVID test will be utilised for T cell testing in a clinical study called the Covid infection in patients with antibody deficiency (COV-AD), to assess the clinical course of the SARS-CoV-2 infection and the immunological response of patients to vaccines. The study is being carried out in collaboration with the University of Birmingham and aims to collect samples from 13 sites across the UK. The study will establish whether individuals with antibody deficiency mount durable immune responses, and if not, the impact it has on the virus.
221b Foundation, a non-profit organisation started by biotechnology company Sherlock Biosciences, has offered a licence to Rokline Health Concepts for developing and manufacturing Covid-19 diagnostic test kits using Sherlock’s CRISPR technology. The agreement aims to increase testing capacity across the US and offers a path for the development and delivery of high-throughput, accurate and automatable solutions like the SHERLOCK to directly benefit Covid-19 patients.
Applied DNA Clinical Labs, a subsidiary of biotechnology company Applied DNA Sciences, has received a Clinical Laboratory Improvement Amendments (CLIA) certification from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for high throughput diagnostic Covid-19 testing, using methods and devices authorised for emerhttps://www.businesswire.com/news/home/20210511005756/en https://adnas.com/clia-certification-diagnostic-covid-19-testing/https://www.businesswire.com/news/home/20210511005756/en https://adnas.com/clia-certification-diagnostic-covid-19-testing/gency use, including the company’s Linea Covid-19 Assay Kit.
